The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy
Open accessAbstract
BACKGROUND: Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable symptoms despite maximal medical therapy, but is associated with morbidity and mortality. OBJECTIVES: This study sought to determine whether the oral myosin inhibitor mavacamten enables patients to improve sufficiently to no longer meet guideline criteria or choose to not undergo SRT. METHODS: Patients with left ventricular (LV) outflow tract (LVOT) gradient ≥50 mm Hg at rest/provocation who met guideline criteria for SRT were randomized, double blind, to mavacamten, 5 mg daily, or placebo, titrated up to 15 mg based on LVOT gradient and LV ejection fraction. The primary endpoint was the composite of the proportion of patients proceeding with SRT or who remained guideline-eligible after 16 weeks' treatment. RESULTS: One hundred and twelve oHCM patients were enrolled, mean age 60 ± 12 years, 51% men, 93% New York Heart Association (NYHA) functional class III/IV, with a mean post-exercise LVOT gradient of 84 ± 35.8 mm Hg. After 16 weeks, 43 of 56 placebo patients (76.8%) and 10 of 56 mavacamten patients (17.9%) met guideline criteria or underwent SRT, difference (58.9%; 95% CI: 44.0%-73.9%; P < 0.001). Hierarchical testing of secondary outcomes showed significant differences (P < 0.001) favoring mavacamten, mean differences in post-exercise peak LVOT gradient -37.2 mm Hg; ≥1 NYHA functional class improvement 41.1%; improvement in patient-reported outcome 9.4 points; and NT-proBNP and cardiac troponin I between-groups geometric mean ratio 0.33 and 0.53. CONCLUSIONS: In oHCM patients with intractable symptoms, mavacamten significantly reduced the fraction of patients meeting guideline criteria for SRT after 16 weeks. Long-term freedom from SRT remains to be determined. (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]; NCT04349072).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31792-x · Cited by 1,296
Self-citation2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.011 · Cited by 1,276
Self-citationMaron, M. S., Olivotto, I., Betocchi, S., Casey, S. A., Lesser, J. R., Losi, M. A., Cecchi, F., & Maron, B. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021332 · Cited by 1,259
Ommen, S. R., Maron, B. J., Olivotto, I., Maron, M. S., Cecchi, F., Betocchi, S., Gersh, B. J., Ackerman, M. J., McCully, R. B., Dearani, J. A., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.090 · Cited by 812
Self-citationBRAUNWALD, E., LAMBREW, C. T., ROCKOFF, S. D., ROSS, J., & MORROW, A. G. (1964) · Circulation · doi:10.1161/01.cir.29.5s4.iv-3 · Cited by 758
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.045 · Cited by 643
Self-citationDiagnosis and Evaluation of Hypertrophic Cardiomyopathy
Maron, B. J., Desai, M. Y., Nishimura, R. A., Spirito, P., Rakowski, H., Towbin, J. A., Rowin, E. J., Maron, M. S., & Sherrid, M. V. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.002 · Cited by 637
Self-citationElliott, P. M., Gimeno, J. R., Tomé, M. T., Shah, J., Ward, D., Thaman, R., Mogensen, J., & McKenna, W. J. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl041 · Cited by 427
Management of Hypertrophic Cardiomyopathy
Maron, B. J., Desai, M. Y., Nishimura, R. A., Spirito, P., Rakowski, H., Towbin, J. A., Dearani, J. A., Rowin, E. J., Maron, M. S., & Sherrid, M. V. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.021 · Cited by 398
Self-citation
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001250 · Cited by 807
Self-citation2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · JACC · doi:10.1016/j.jacc.2024.02.014 · Cited by 382
Self-citationAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Maron, M. S., Masri, A., Nassif, M. E., Barriales-Villa, R., Arad, M., Cardim, N., Choudhury, L., Claggett, B., Coats, C. J., Düngen, H.-D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401424 · Cited by 348
Self-citationMavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy
Desai, M. Y., Owens, A. T., Abraham, T., Olivotto, I., Garcia-Pavia, P., Lopes, R. D., Elliott, P., Fernandes, F., Verheyen, N., Maier, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505927 · Cited by 90
Self-citation
Metadata
- Authors
- Desai, M. Y., Owens, A., Geske, J. B., Wolski, K., Naidu, S. S., Smedira, N. G., Cremer, P. C., Schaff, H., McErlean, E., Sewell, C., Li, W., Sterling, L., Lampl, K., Edelberg, J. M., Sehnert, A. J., & Nissen, S. E.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 80
- Issue
- 2
- Pages
- 95-108
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W4283804747
- Cited by
- 376
- References
- 28
- FWCI
- 47.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. https://app.cochat.ai/papers/10.1016/j.jacc.2022.04.048
- The paper
- Desai, M. Y., Owens, A., Geske, J. B., Wolski, K., Naidu, S. S., Smedira, N. G., Cremer, P. C., Schaff, H., McErlean, E., Sewell, C., Li, W., Sterling, L., Lampl, K., Edelberg, J. M., Sehnert, A. J., & Nissen, S. E. (2022). Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2022.04.048
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.